Atara Biotherapeutics (ATRA) stock jumps as an FDA top official reportedly overruled internal reviewers in rejecting the company's cell therapy. Read more here.
Linked to North Korean fake job-recruitment campaigns, the poisoned repositories are aimed at establishing persistent C2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results